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Introduction: Silk fibroin (SF) scaffolds have been shown to be a suitable substrate for tissue engineering and to
improve tissue regeneration when cellularized with mesenchymal stromal cells (MSCs). We here demonstrate, for
the first time, that electrospun nanofibrous SF patches cellularized with human adipose-derived MSCs (Ad-MSCs-SF),
or decellularized (D-Ad-MSCs-SF), are effective in the treatment of skin wounds, improving skin regeneration in
db/db diabetic mice.
Methods: The conformational and structural analyses of SF and D-Ad-MSCs-SF patches were performed by
scanning electron microscopy, confocal microscopy, Fourier transform infrared spectroscopy and differential
scanning calorimetry. Wounds were performed by a 5 mm punch biopsy tool on the mouse’s back. Ad-MSCs-SF
and D-Ad-MSCs-SF patches were transplanted and the efficacy of treatments was assessed by measuring the wound
closure area, by histological examination and by gene expression profile. We further investigated the in vitro
angiogenic properties of Ad-MSCs-SF and D-Ad-MSCs-SF patches by affecting migration of human umbilical vein
endothelial cells (HUVECs), keratinocytes (KCs) and dermal fibroblasts (DFs), through the aortic ring assay and, finally,
by evaluating the release of angiogenic factors.
Results: We found that Ad-MSCs adhere and grow on SF, maintaining their phenotypic mesenchymal profile and
differentiation capacity. Conformational and structural analyses on SF and D-Ad-MSCs-SF samples, showed that
sterilization, decellularization, freezing and storing did not affect the SF structure. When grafted in wounds of
diabetic mice, both Ad-MSCs-SF and D-Ad-MSCs-SF significantly improved tissue regeneration, reducing the wound
area respectively by 40% and 35%, within three days, completing the process in around 10 days compared to
15–17 days of controls. RT2 gene profile analysis of the wounds treated with Ad-MSCs-SF and D-Ad-MSCs-SF
showed an increment of genes involved in angiogenesis and matrix remodeling. Finally, Ad-MSCs-SF and
D-Ad-MSCs-SF co-cultured with HUVECs, DFs and KCs, preferentially enhanced the HUVECs’ migration and the
release of angiogenic factors stimulating microvessel outgrowth in the aortic ring assay.
Conclusions: Our results highlight for the first time that D-Ad-MSCs-SF patches are almost as effective as Ad-MSCs-SF
patches in the treatment of diabetic wounds, acting through a complex mechanism that involves stimulation of
angiogenesis. Our data suggest a potential use of D-Ad-MSCs-SF patches in chronic diabetic ulcers in humans.* Correspondence: stefania.navone@unimi.it
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Impaired wound healing is a major clinical problem in
diabetic patients. A definitive pharmacological treatment
of this pathological condition is currently unavailable
and this often leads to limb amputation [1].
Cell-based therapies are slowly gaining ground in rou-
tine medical care and, especially, in wound management
of skin. They offer promise for the repair and/or replace-
ment of damaged tissue and the restoration of lost func-
tionality because they possess many of the criteria
necessary for wound healing [2,3].
Reports increasingly suggest that multipotent mesenchy-
mal stromal cells (MSCs), isolated from different tissue
sources, confer benefits in vivo as tissue restorative agents.
They act by either releasing trophic factors or through
their multilineage differentiation properties [3,4]. In par-
ticular, adipose tissue derived MSCs (Ad-MSCs) are cur-
rently under investigation to treat skin wounds [5] because
of their abundance, easy isolation and in vitro expansion.
Recently, several different biosynthetic scaffolds, both
bioresorbable and non-resorbable, have been used alone
or in combination with cells to treat wounds [6-9].
Among the different scaffolds, silk fibroin (SF), loaded
with MSCs, has been shown to possess some efficacy in
repairing experimental wounds of the skin [10,11]. How-
ever, the application of scaffolds loaded with live cells
in vivo may have some risk, due to the possible transfer
of pathogens or the induction of adverse immunological
reaction in the host, particularly when allogenic or xeno-
genic cells are utilized for therapy [12-14].
For these reasons, decellularized scaffolds have also re-
ceived significant interest for tissue engineering applica-
tions [14-19]. It has been suggested that decellularized
biological scaffolds may mimic a natural extracellular
matrix (ECM) substrate. Moreover, decellularized scaffolds
previously coated with cells or cultured cell-derived ECM
scaffolds, once transplanted in vivo, may mimic the pres-
ence of living cells, possibly through a slow release process
of cell products which have remained entrapped in the
scaffold’s mesh [15-20]. Furthermore, the methods to re-
move the cells from the scaffold, in general, alter neither
the three-dimensional native architecture of the scaffold
nor the cell products [20,21].
In this study, we wanted to investigate the efficacy
of SF patches, cellularized with human Ad-MSCs (Ad-
MSCs-SF) or decellularized (D-Ad-MSCs-SF) by using
distilled water, on experimental skin wounds in diabetic
mice (db/db Leprdb/J). These mice carry a mutation in
the leptin receptor that determines a significant delay
in wound healing similar to that observed in diabetic
patients [22].
We assessed the efficacy of treatments by measuring
the wound closure area and by histological examination.
Concomitantly, we investigated the gene expression inthe regenerating tissue by RT2 profile, as well as the
in vitro capacity of cellularized and decellularized SF
patches to affect migration of human umbilical vein
endothelial cells (HUVECs), keratinocytes (KCs) and
dermal fibroblasts (DFs) and their angiogenic properties.
Our data show, for the first time, that D-Ad-MSCs-SF
patches are almost as effective in the treatment of skin
wounds as the cellularized ones.
Methods
Cell isolation and culture
The study was approved by the local institutional review
board of the IRCCS Foundation Neurological Institute
‘C. Besta’, Milan Italy and informed written consent was
obtained from all volunteers.
Specimens of fat from the periumbilical regions of four
volunteers were collected by a lipoaspirate technique.
Ad-MSCs were obtained as previously described [23].
The cells were cultured in stem cell medium (SCM),
consisting of (D)MEM/F12 supplemented with 10% fetal
bovine serum (Gibco, Grand Island, NY, USA), 1% peni-
cillin and streptomycin solution (Sigma-Aldrich, Basel,
Switzerland) and optimized for the growth of stem cells
as previously described [24]. The Ad-MSCs were rou-
tinely seeded at 2 × 104 cells/cm2 in T75-cm2 flasks and
passed weekly. For experiments, the cells were not used
after six passages. Cell viability was assessed by the try-
pan blue dye-exclusion assay.
Flow cytometric analysis
Flow cytometry (FC) was performed on Ad-MSCs to
evaluate mesenchymal, hematopoietic, endothelial and
immunological markers: CD14, CD31, CD34, CD45,
CD73, HLA-DR (BD Pharmingen, San Jose, CA, USA),
CD105 (AbDSerotec, Raleigh, NC, USA), CD90 (Milli-
pore, Temecula, CA, USA) and CD19 (Beckman Coulter,
Milan, Italy). Briefly, 5 × 104 cells/tube were stained with
fluorochrome conjugated monoclonal antibodies (mAbs)
and incubated for 30 minutes at 4°C in the dark. Sam-
ples were centrifuged at 300 × g for five minutes, washed
twice with PBS and fixed with 4% paraformaldehyde
(PFA) (Sigma-Aldrich). Analyses were performed in a
scan flow cytometer by means of Cell Quest software
(BD Pharmingen). Isotype-matched mouse immunoglob-
ulins were used as control. At least 2 × 104 events were
acquired for each sample. Non-viable cells were ex-
cluded by physical gating.
Multipotent differentiation potential of Ad-MSCs before
and after seeding on SF patches
According to the minimal criteria suggested by Dominici
et al. [25], Ad-MSCs were tested for their capacity to
differentiate into adipocytes, chondrocytes and osteo-
cytes, before and after seeding on SF scaffold. Briefly, to
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were plated onto micro cover glasses (Zeus Scientific,
Branchburg, NJ, USA) or onto SF patch in 24 multi-well
plates (Sigma-Aldrich) with 0.5 mL/well of SCM. After
48 hours of incubation at 37°C, 5% CO2, the culture
medium was replaced with adipogenesis differentiation
medium (ADM). After 21 days of culture, cells were
washed two times with D-PBS, fixed for 30 minutes at
room temperature with 4% PFA and stained with Oil
Red O (Sigma-Aldrich) [26].
Osteogenic differentiation was obtained by incubating
cells in osteogenesis differentiation medium (ODM) for
21 days. Cultured monolayers were fixed for five minutes
in cooled ethanol at 70% and then processed for Alizarin
Red staining (Sigma-Aldrich) [26].
Chondrogenic differentiation was performed using a
Human Mesenchymal Stem Cell Functional Identification
kit (R&D System, Minneapolis, USA) following the manu-
facturer’s instructions. After 21 days of incubation in
chondrogenesis differentiation medium (CDM), the pellet
was fixed for 30 minutes at room temperature with 4%
PFA, cryoprotected with 30% sucrose (Sigma Aldrich) in
D-PBS, embedded in optimal cutting temperature (OCT)
compound (Sakura Finitek, Torrance CA, USA) and sec-
tioned using a cryostat (Leica). The slides were processed
for immunocytochemical detection of aggrecan. Negative
controls (cells in SCM culture medium) were performed
to evaluate the specificity of the antibody.
Histological and immunohistochemistry stainings were
performed on Ad-MSCs-SF after 21 days of adipogenic,
osteogenic and chondrogenic differentiation culture con-
ditions in ADM, ODM and CDM, respectively. Briefly,
the Ad-MSCs-SF patches were fixed for 30 minutes at
4°C in 4% PFA in 0.1 M D-PBS and cryoprotected with
30% sucrose (Sigma Aldrich) in D-PBS, embedded in
OCT compound (Sakura Finitek) and sectioned on a
cryostat (Leica). Oil Red O, Alizarin Red (Sigma-Aldrich)
and aggrecan (1:100, R&D System) stainings were used
to confirm adipogenic, osteogenic and chondrogenic dif-
ferentiation capabilities.
Preparation of Ad-MSCs- SF and D-Ad-MSCs-SF patches
Sheets of electrospun SF were produced according to the
method of Alessandrino et al. [27]. Five-mm-diameter SF
patches were cut by using a sterile 5-mm punch biopsy
tool (KLS Martin cod. 28-240-05-07 Umkirch, Germany),
placed into Petri dishes, washed with 70% ethanol solu-
tion for one hour, sterilized under UV light for six hours
and then stored at 4°C until use.
Each patch was placed into a well of a 96-multiwell plate
(Corning Incorporated, Corning, NY, USA) and seeded
with a suspension of 3 × 104 Ad-MSCs in 200 μL of SCM.
Cellularized patches were incubated at 37°C for at least
seven days in a humidified atmosphere containing 5%CO2. Concomitantly, control patches with 200 μL of
medium without cells were incubated under the same
conditions. The medium was changed once. The decellu-
larization procedure for the SF patches was performed by
removing the culture medium, washing the patches with
sterile distilled H2O at 4°C and incubating them with dis-
tilled MilliQ water for 30 minutes at 4°C. The D-Ad-
MSCs-SF patches were then transferred into a new well
and stored under different conditions: in distilled water at
4°C, under dry conditions at 4°C, frozen in distilled water
at −20°C, or frozen under dry conditions at −20°C. D-Ad-
MSCs-SF patches stored for more than seven days were
not used in vivo.
Conformational analysis of untreated and D-Ad-MSCs-SF
patches
Conformational analysis was performed on untreated
and decellularized patches to test whether sterilization,
decellularization, and different storing conditions could
affect the SF structure.
Fourier transform-infrared (FTIR) spectroscopy mea-
surements were performed on a NEXUS (Thermo Nico-
let) FTIR spectrometer employing an attenuated total
reflectance (ATR) accessory model, Smart Performer. All
spectra were obtained with a ZnSe crystal cell as the in-
ternal reflection element. Spectra were recorded in the
400 to 4,000 cm-1 wave number range by accumulating
64 scans at a resolution of 4 cm-1, subjected to data
smoothing (15 points with the Savitzky-Golay method)
and normalized to the 1,452 cm-1 peak before any data
processing. Each spectrum was the average of at least
three spectra measured in different areas of the sample.
The crystallinity index was calculated as the intensity ra-
tio between the two amide III components at 1260 cm-1
and 1230 cm-1 (C.I. = I1260/I1230) [28].
Differential scanning calorimetry (DSC) measurements
were performed with a DSC Q200 instrument (TA Instru-
ments, Waters, Milan, Italy). The scanned temperature
ranged from room temperature to 400°C, at a heating rate
of 10°C/minute. The analysis was carried out on samples
of about 2 to 3 mg weight, in open aluminum pans of
40 μL volume, under N2 gas flux.
Morphological analysis of SF, Ad-MSCs-SF and D-Ad-
MSCs-SF patches
The morphology of SF, Ad-MSCs-SF and D-Ad-MSCs-
SF patches was investigated by standard histology and by
scanning electron microscopy (SEM) to evaluate the effi-
cacy of cellularization and the presence of alterations
in fibroin structure induced by sterilization, decellulari-
zation and different storing conditions. For histology,
the samples were fixed in 10% neutral-buffered formalin,
dehydrated and embedded in paraffin wax. Sections 5 μm
thick were mounted on glass slides and stained with
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cacodylate buffer (CB), fixed with 2.5% glutaraldehyde
(Sigma-Aldrich) in CB for two hours at 4°C and dehy-
drated in a graded series of ethanol up to absolute. Ad-
MSCs-SF and D-Ad-MSCs-SF patches were placed on
metal stubs, coated with gold to a thickness of 15 nm and
viewed using a Philips XL30 scanning electron microscope
(Center for Electron Microscopy - CUME, University of
Perugia, Perugia, Italy).
Immunophenotype
Ad-MSCs-SF patches were also subjected to immuno-
fluorescence to confirm the maintenance of the Ad-MSC
phenotype after cultivation on SF. Briefly, Ad-MSCs-SF
cultured for seven days on SF patches were fixed for 30
minutes at room temperature in 4% PFA. The patches
were permeabilized with 0.1% Triton X-100. The following
primary antibodies were applied overnight at 4°C: mouse
anti-human CD44 (1:500), CD45 (1:400), CD146 (1:400)
and rabbit anti-human CD49d (1:500) (all purchased
from Chemicon-Millipore, Temecula, California, USA).
Cells were then incubated in Cy3-, and/or Cy2-conjugated
secondary antibodies (Jackson ImmunoResearch, West
Grove, PA, USA) at room temperature for 45 minutes and
mounted with Fluorsave™ (Merck-Millipore, Nottingham,
UK). The three-dimensional digital images were made
using a Leica TCS SP2 AOBS (Leica Microsystems,
Wetzlar, Germany) confocal laser scanning microscope.
Surgical procedure: engraftment of Ad-MSCs-SF and
D-Ad-MSCs-SF patches in diabetic (Leprdb/db) mice
Procedures involving animals were conducted in conform-
ity with institutional guidelines in compliance with the
Italian guidelines for animal care (DL 116/92), the
European Community Council Directive (86/609/EEC)
and the National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals. The protocol
for the use of laboratory animals was approved by the
Italian Ministry of Health and by an internal ethics com-
mittee. All surgery was performed under chloral hydrate
anesthesia and all efforts were made to minimize suffering.
Eight-week old Lepr db/db male mice (Charles River
Laboratories, Calco, Lecco, Italy) were housed for at least
one week in their home cages at a constant temperature.
Mice were randomized into four groups of six each. Control
no-graft mice received only saline and treated mice received
SF, Ad-MSCs-SF and D-Ad-MSCs-SF patches, respectively.
Briefly, mice were anesthetized with chloral hydrate
(4%, 400 mg/kg i.p) and one wound on each side of the
mouse’s back midline extending through the panniculus
carnosus was made with a sterile 5-mm punch biopsy
tool (KLS Martin cod. 28-240-05-07 Germany). Patches
were applied on the wounds and fixed to the skin with
30 μL of Hydrogel (ExtracelTM -X Maxi Hydrogel Kit,Glycosan BioSystems Inc. Alameda, CA, USA) ensuring
prolonged adhesion to the wound. Mice were placed in
individual home cages.
Mice were photographed postoperatively at three and
ten days using a Canon high-resolution digital camera.
Wound closure areas were measured as previously de-
scribed [29]. Briefly, a metric ruler was placed adjacent
to the wound limit and three individual photomicro-
graphic measurements were taken for each mouse. The
percentage of wound closure (contraction) was calcu-
lated with the formula: area at postoperative day 0 - area
at postoperative day x/ area at postoperative day 0 × 100.
All measurements were independently evaluated by two
investigators blinded to the randomization.
Specimens of mouse skin treated with control SF, Ad-
MSCs-SF and D-Ad-MSCs-SF patches were collected
after transplants. Skin samples were fixed in 10% neutral
buffered formalin, paraffin embedded, stained with H&E
and examined histologically for the following main param-
eters: re-epithelialization, neovascularization and dermal
fiber organization.
Immunohistochemical analysis of Ad-MSCs-SF and
D-Ad-MSCs-SF patches after transplantation
Tissue samples were collected 14 days after transplant-
ation, fixed in 10% neutral buffered formalin and paraf-
fin embedded. Immunohistochemistry was performed
on 5 μm thick serial sections mounted on poly-l-lysine
coated glass slides. After deparaffinization, endogenous
peroxidase activity was quenched with 3% hydrogen per-
oxide in water. Sections were then microwaved for 15
minutes in 10 mM citric acid (pH 6.0) for antigen re-
trieval and treated with normal goat serum (Dako Cor-
poration, Carpinteria, CA, USA) 1:10 for 30 minutes to
prevent non-specific binding of primary antibodies. Sub-
sequently, sections were incubated overnight at room
temperature with the following primary antibodies:
rabbit polyclonal anti-collagen IV antibody diluted 1:100
(Abcam, Cambridge, UK), mouse monoclonal anti-VEGF
antibody diluted 1:100 (Abcam, Cambridge, UK), mouse
monoclonal anti-human nuclei (HuNu) antibody diluted
1:50 (Merck Millipore, Billerica, MA, USA). The next
day, after washing in PBS, the sections were incubated
for 30 minutes at room temperature with the corre-
sponding secondary biotin-conjugated antibody: goat
anti-mouse immunoglobulin G (IgG) (for anti-HuNu
and anti-VEGF) and goat anti-rabbit IgG (for anti-
collagen IV antibody). Bound antibodies were revealed
with avidin–biotin–peroxidase complex (Vector Elite kit,
Vector Laboratories, Burlingame, CA, USA). The reaction
was finally visualized by exposure to fresh diaminobenzi-
dine chromogen substrate solution (Vector Laboratories).
Negative controls without the primary antibody were run
in parallel. Tissue observation was carried out using a light
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Tokyo, Japan) connected to a digital camera (Dxm 1200
Nikon digital camera).
Scratch test
The scratch assay was set up with an Ibidi Culture-
Insert (Ibidi GmbH, Münich, Germany). Briefly, Ibidi
Culture-Inserts were placed on the bottom of wells in a
24-multiwell plate coated with 0.2 mg/mL of collagen
type I solution (Sigma-Aldrich). Human KCs, DFs and
HUVECs (all purchased from Centro Substrati Cellulari,
ISZLER, Brescia, Italy) were seeded to a final density of
5 × 103 cell/cm2 onto an Ibidi Culture-Insert in SCM.
The cells were maintained for 24 hours at 37°C and 5%
CO2 to allow cell monolayer formation. Thereafter, the
Ibidi Culture-Insert was removed, cells were gently
washed with PBS, and 0.5 mL of SCM (without additional
growth factors) was added. Next, transwells 8 μm polycar-
bonate membrane inserts filter (Corning Life Sciences)
were placed on the well and then SF, Ad-MSCs-SF and
D-Ad-MSCs-SF patches were located on the transwells
and rapidly filled with 200 μL of SCM. After 24 hours or
48 hours, transwells were removed and cells were observed
under a Zeiss Axiophot-2. To evaluate the reparative ef-
fects of SF patches, cells migrated into the inter-space were
counted under microscopy at 20 ×magnification in five
random fields. Each migration test was run in triplicate.
At the end of the HUVECs scratch test, aliquots of con-
ditioned medium (CM) were collected and, according to
the manufacturer’s instructions, human FGF2, EGF (Mini
ELISA Development kit purchased from Peprotech, Rocky
Hill, New York, USA), TGFβ (Demeditec, Kiel-Wellsee,
Germany) and VEGF (Ray Biotech, Inc, Georgia, USA)
were quantified by ELISA in accordance with the standard
guideline protocol supplied with the kits. The background
value (<10%) of each growth factor contained in the SCM
medium was assessed. Absorbance was measured at
450 nm or 405 nm with a microplate photometric reader
DV990BV4 (GDV, Milan, Italy). The results were normal-
ized with the CM obtained by the co-culture of HUVEC
with SF patches and were expressed as mean ± SD of the
secreted factor. The assay was repeated twice and each
sample was run in triplicate.
Quantitative reverse transcriptase–polymerase chain
reaction
Reverse transcriptase–polymerase chain reaction (RT-
PCR) was performed on Ad-MSCs cultured on plastic and
on SF patches. For the analysis of mRNA levels, 500 ng of
total RNA isolated using the RNeasy kit (Qiagen, Milan,
Italy) was reverse-transcribed using an iScript cDNA Syn-
thesis Kit (Bio-Rad Laboratories). Triplicate PCRs were
carried out on an iCycler iQ Real Time PCR Detection
System (Bio-Rad Laboratories, Milan, Italy). Relative geneexpression was calculated by a comparative method
(2-ΔΔCt) using GAPDH as a housekeeping gene. Primer
sequences were designed using Primer3 software.
Gene profile
Specimens of skin tissue were excised and analyzed for
gene profile. Briefly, 500 ng of total RNA was used for
each plate and was reverse-transcribed using RT2 First
Strand Kit (SABioscience Corporation, Frederick, MD,
USA), according to the manufacturer’s instructions. The
RT2 Profiler™ PCR array for mouse wound healing
(PAMM-121, SABioscience Corporation) was performed
in triplicate for each sample to compare quantitative
PCR (Q-PCR)–validated murine cDNA samples. Plates
were run in Applied Biosystem AB 7300 real-time PCR,
according to the manufacturer’s instructions. Relative
gene expression was calculated using RT2 Profiler™ PCR
array data analysis (SABioscience).
Rat aortic ring assay
The rat aorta ring assay was also performed to investi-
gate the angiogenic potential of Ad-MSCs-SF- and D-
Ad-MSCs-SF-derived CMs during HUVECs scratch test.
The aorta ring assay was performed as previously de-
scribed [30]. Briefly, the dorsal aorta was excised from
six-week-old Sprague–Dawley rats (Charles River La-
boratories). Around 1 mm-thick rings were prepared.
The rings were placed in a collagen solution prepared as
described [31]. Around 40 μL of collagen solution was
placed in each well and then one aortic ring/well was
placed into the collagen solution. The plates were then
incubated in a humidified incubator at 37°C for 30 mi-
nutes to obtain collagen jellification. At the end of incuba-
tion, the wells were filled with 500 μL of endothelial basal
medium (EBM, LONZA, Walkersville, MD, USA) con-
taining control medium, or SF, Ad-MSCs-SF and D-Ad-
MSCs-SF derived CMs. The plates were incubated for 10
to 12 days. Quantification of angiogenesis was obtained by
taking photographs with a Zeiss microscope at 10 ×mag-
nification every three days and by counting the number of
microvessels arising from the aorta rings [29].
Statistical analysis
The results are expressed as mean ± SD in replicate with
n ≥3. One way analysis of variance (ANOVA) two-tailed
test was utilized for all statistical analyses and performed
with GraphPad Prism software, version 4.0. P values of
less than 0.05 were considered to be significant.
Results
SF patches support adhesion and growth of Ad-MSCs
Cultured human Ad-MSCs showed a typical fibroblas-
tic–like morphology (Additional file 1: Figure S1A). FC
analysis of multiple surface epitopes showed that Ad-
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CD14, CD34 and CD45, endothelial marker CD31 and
immunological markers CD19 and HLA-DR. In contrast,
Ad-MSCs highly expressed (≥90%) MSC markers, such
as CD73, CD90 and CD105 (Additional file 1: Figure S1B).
Moreover, when cultured under differentiation condi-
tions, Ad-MSCs were able to differentiate towards adi-
pocytes, osteocytes and chondrocytes (Additional file 1:
Figure S1C-E). In order to investigate whether SF
patches could support attachment, proliferation and
maintenance of the phenotypic profile of Ad-MSCs,
we seeded and cultured them on SF patches for seven
days. We then analyzed their morphology by light
microscopy and by SEM and evaluated their marker
expression by immunofluorescence. SEM showed that
the untreated SF patches appeared to be constituted of
filamentous material consisting of nanofibers (Figure 1A).
After the seeding, they were rapidly colonized by Ad-
MSCs (Figure 1B) that formed a uniform and compact
monolayer within seven days (Figure 1C). This result
was also observed using light microscopy after H&E
staining (Figure 1D). Confocal light microscopy further
demonstrated that the Ad-MSCs cultured on SF patches
maintained their phenotypic profile and were positive
for the mesenchymal markers CD146 (Figure 1E) and
CD44 (Figure 1F) and for the integrin CD49d (Figure 1G).
Cells seeded on patches confirmed their negativity for
the hematopoietic marker CD45 (Figure 1H). Moreover,
when cultured on SF under differentiation conditions,
the Ad-MSCs maintained the ability to differentiate to-
wards the adipocytes, osteocytes and chondrocytes as
demonstrated by Oil O Red and Alizarin Red staining
and by aggrecan expression (Additional file 2: Figure
S2A-C).
We next analyzed the morphology of SF patches after
decellularization in order to validate our procedure. H&E
staining (Figure 1I), as well as SEM analysis (Figure 1J),
were performed on decellularized SF patches, demonstrat-
ing that the use of deionized MilliQ H2O for one hour
was effective in removing all Ad-MSCs. The morpho-
logical analysis showed that after H2O treatment the cells
were completely removed from the patches and no cell
fragments remained entrapped within the SF patches. Fur-
thermore, there was no apparent disruption of the archi-
tecture of the SF patches, as assessed by SEM analysis; in
particular, the random arrangement typical of the SF fibers
was maintained (Figure 1I-J).
FTIR and DSC were performed to assess the stability
of untreated and D-Ad-MSCs-SF patches and to evaluate
the influence of sterilization, decellularization, freezing
(−20°C) and storing (4°C) under dry or wet conditions
on intramolecular interactions.
FTIR and DSC analyses showed that the molecular
and structural properties of SF patches were not affectedby the decellularization process (Additional file 2: Figure
S2D-E). The intrinsic crystalline structure of the SF
patches did not change after the described treatments.
Moreover, DSC analysis revealed that the presence and
intensity of characteristic thermal transitions (glass tran-
sition, melting, degradation) recorded during heating
may reflect typical structural features of the sample, SF
alone, as demonstrated by the closely similar profiles re-
ported in Additional file 2: Figure S2E. These results
confirm that the SF patches were stable under the chem-
ical and biological stressing conditions adopted in this
study, in accordance with morphological data obtained
by SEM analysis (see Figure 1I-J).
Ad-MSC-SF and D–Ad-MSCs-SF improve skin healing in
db/db diabetic mice
Diabetic db/db strain mice were used for in vivo tests.
Each mouse underwent a 5-mm skin lesion with a sterile
punch biopsy tool in a surgical procedure.
Wound closure was measured by planimetric analysis
which revealed a strong increment of wound healing in
mice treated with cellularized and, also, with decellularized
SF scaffolds (Figure 2). In particular, wound closure at
postoperative day 3 was 9.5% ± 0.5 in the control group,
11.5% ± 0.8 in the SF group, 49% ± 0.8 in the D-Ad-MSCs-
SF group and 50% ± 2.4 in the Ad-MSCs-SF. Evaluations
of the reduction of the wound area at postoperative day 10
were 50% ± 2.4 in the no graft group, 48% ± 1.9 in the SF
group, 94% ± 2.9 in D-Ad-MSCs-SF group and 99.84% ±
1.9 in the Ad-MSCs-SF group (Figure 2A). The area of
the wound was measured by using a metric ruler that was
placed adjacent to the wound as shown in Figure 2B. In
Figure 2C the photographs indicating the kinetics of
wound healing in all groups are shown. Almost a complete
epithelialization of the wound was reached around postop-
erative day 10 in mice treated with either cellularized or
decellularized SF scaffold, while 15 to 17 days were neces-
sary in control and SF grafted mice. The histological
examination showed that the wound healing in control
and in SF treated mice was delayed compared to Ad-
MSCs-SF and D-Ad-MSCs-SF treated mice. However, at
14 days of treatment, those mice treated with Ad-MSCs-
SF showed a higher degree of tissue organization not only
in comparison with those treated only with the SF control,
but even with those who received D-Ad-MSCs-SF patches.
Indeed, epidermis and collagen fibers appeared well reor-
ganized and even new hair follicles were present. In
addition, a significant increment of microvascular density
was observed (Additional file 3: Figure S3).
Ad-MSCs-SF and D-Ad-MSCs-SF enhance the expression of
genes involved in angiogenesis in vivo
During in vivo wound regeneration, a sample of mice
was sacrificed and tissues from the wound were removed
Figure 1 Morphological appearance of SF patches seeded with Ad-MSCs before and after decellularization. On SEM, untreated SF
patches show their typical filamentous structure (A). In B and C, SF patches seeded with Ad-MSCs after two and seven days of culture,
respectively. Note that at seven days the Ad-MSCs formed an almost uniform monolayer on SF patches (Scale bar 20 μm). This result was also
seen on light microscopy after H&E staining (D); note that Ad-MSCs (arrows) have a spindle-shape morphology (asterisks indicate cell nuclei)
(Scale bar 30 μm). After seven days of culture, Ad-MSCs-SF analyzed by confocal microscopy maintain the positive expression of mesenchymal
markers CD146 (E) and CD44 (F) and of the integrin CD49d (G) and the negativity for the hematopoietic marker CD45 (H). Incubation of
Ad-MSCs-SF with distilled H20 for one hour was effective in completely removing the cells from SF patches. H&E staining (I): no cellular elements
remain attached on SF patches after decellularization; the pink spots (arrows) represent fibroin aggregates (Scale bar 20 μm). SEM
(J): note the absence of cell debris (Scale bar 50 μm). In the figure: SF = silk fibroin; c = flattened Ad-MSCs. Ad-MSCs, adipose tissue derived
mesenchymal stromal cells; SEM, scanning electron microscopy.
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profiler of Ad-MSCs-SF and D-Ad-MSCs-SF versus SF
transplants is shown in Figure 3. In summary, mice
treated with Ad-MSCs-SF showed a significant up-
regulation of several genes involved in angiogenesis
and in tissue regeneration, such as Vegfa, Egf, Pdgfa,
Wnt5α, Wisp1 and Tgfβr3. In addition, genes involved
in ECM deposition and remodeling such as Mmp2,
Itgβ6, Col5α1, Col5α2, Col4α1 and Tagln were signifi-
cantly increased. Conversely, we found a down-regulation
of genes involved in collagen type 3 synthesis (Col3α1),
adhesion and cytoskeleton organization (Itgα6, Itgβ1,
Actα2). Genes involved in immunomodulation and in-
flammation, such as Il6st, were significantly increased,
whereas macrophage migration inhibitor factor (Mif) wasslightly down-regulated (Figure 3A). Although, less than
in Ad-MSCs-SF, the RT2 gene profiler analysis of D-Ad-
MSCs-SF treated mice revealed an increment of some
genes involved in angiogenesis (Wnt5α, Egf), ECM depos-
ition and remodeling (Col4α1, Tagln), as well as a down-
modulation of genes involved in cytoskeleton organization
(Itgα6, Itgβ1, Actα2). In general, in mice treated with D-
Ad-MSCs-SF, inflammatory genes were not up-modulated
and Mif was significantly down-regulated (Figure 3B).
Immunohistochemistry of the tissues from the mice
that received Ad-MSCs-SF and D-Ad-MSCs-SF patches
was also investigated for the angiogenic marker Vegf
and for Col4α1 involved in basal membrane.
Expression of Col4α1 was observed in every sample.
Basal membrane was continuously and sharply stained in
Figure 2 Ad-MSCs-SF and D-Ad-MSCs-SF accelerate wound healing in diabetic mice. Diabetic db/db strain mice were used for in vivo
experiments. The different SF patches were applied on the wounds and fixed to the skin with 30 μL of hydrogel. A) shows the kinetics of wound
closure. At each time the wound area was measured by using a metric ruler that was placed adjacent to the wound as shown in B). Each
point at the postoperative day 3, 10, 15 and 20 on the graph are the means ± SD of six mice. Note that on days 3 and 10, mice treated with
Ad-MSCs-SF or with D-Ad-MSCs-SF have a significant increment of the wound closure area (*P <0.05, **P <0.01 versus no graft control). C) shows
the photographs of the wounds taken at postoperative days 0, 3 and 10. Note that in mice treated with Ad-MSCs-SF and D-Ad-MSCs-SF, the skin
wound was significantly reduced compared to either SF or to no graft mice controls. The ameliorative effect was evident even at day 3 after
transplantation. In these mice the wounds were almost healed on day 10. Ad-MSCs-SF, silk fibroin patch cellularized with human adipose-derived
mesenchymal stromal cells; D-Ad-MSCs-SF, silk fibroin patch after human adipose-derived mesenchymal stromal cells removal (decellularization);
SF silk fibroin.
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that the epidermal-dermal junction had been restored
(Additional file 4: Figure S4A-C).
An average of 10 to 12 spindle-shaped Vegf positive
cells per field (100× magnification) were observed in the
dermal layer of Ad-MSCs-SF. Conversely, reactive cells
in D-Ad-MSCs-SF treated samples were less numerous
(2 to 4 per field, at 100× magnification) and were char-
acterized by a less intense staining. A similar number of
Vegf positive cells was detected in SF treated samples
(Additional file 4: Figure S4D-F).
Immunohistochemical staining with anti-HuNu was
also performed to demonstrate the ‘fate’ of human trans-
planted Ad-MSCs in host tissues. The anti-HuNu anti-
body reacted with some cells located in the dermal
layer of Ad-MSCs-SF treated skin. An average of 3 to 4
positive cells per field (100× magnification) was de-
tected. Anti-HuNu reactivity was never observed inD-Ad-MSCs-SF or SF treated skin (Additional file 4:
Figure S4G-I).
Ad-MSCs-SF and D-Ad-MSCs-SF improve migration of
HUVECs
Data from in vivo experiments showed that D-Ad-
MSCs-SF possessed a significant capacity to improve
wound healing in diabetic mice and that it was almost
equal to that obtained with the Ad-MSCs-SF counter-
part. Thus, SF patches could have the ability to work as
a sponge, entrapping the molecules secreted by Ad-
MSCs in vitro that are subsequently released in vivo. In
order to verify that D-Ad-MSCs-SF release molecules
that affect healing, we performed in vitro experiments
on the migration of HUVECs, DFs and KCs by using
the scratch test assay (a scheme of assay is reported in
Additional file 5: Figure S5). As shown in Figure 4, mi-
gration of HUVECs was greatly enhanced under the
Figure 3 Ad-MSCs-SF and D-Ad-MSCs-SF enhance genes involved in angiogenesis and ECM remodeling. On day 7, specimens of skin
tissue were excised and analyzed for gene profile. A significant increment of genes involved in angiogenesis and in tissue regeneration such as
Vegfa, Egf and Pdgfa, Wnt5α, Wisp1 and Tgfβr3 and ECM remodeling (Mmp2, Itgβ6, Col5α1, Col5α2, Col4α1 and Tagln) were observed in
Ad-MSCs-SF compared to SF treated mice (A). Although less than in Ad-MSCs-SF, the RT2 gene profiler analysis of D-Ad-MSCs-SF treated mice
revealed an increment of some genes involved in angiogenesis (Wnt5α, Egf), ECM deposition and remodeling (Col4α1, Tagln), as well as a
down-modulation of genes involved in cytoskeleton organization (Itgα6, Itgβ1, Actα2). In general, in mice treated with D-Ad-MSCs-SF,
inflammatory genes were not up-modulated and Mif was significantly down-regulated (B). The RT2 Profiler™ array for mouse wound healing was
performed in triplicate. Bars in the figure show the relative gene expression increment or decrement that was calculated using RT2 Profiler™ PCR
Array Data Analysis. *P <0.05; **P <0.01 versus untreated SF patches. Ad-MSCs-SF, silk fibroin patch cellularized with human adipose-derived
mesenchymal stromal cells; D-Ad-MSCs-SF, silk fibroin patch after human adipose-derived mesenchymal stromal cells removal (decellularization);
ECM, extracellular matrix; SF, silk fibroin.
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compared to either untreated SF patches or trans-wells
containing only the control medium (Figure 4A). Al-
though less intensive, Ad-MSCs-SF and D-Ad-MSCs-SF
induced a stimulation of DFs migration (Figure 4B)
whereas no stimulation on migration of KCs was observed
(Figure 4C). Interestingly, D-Ad-MSCs-SF patches were
the most efficient in inducing a complete coverage of the
scratch area by HUVECs, which was completed in 48
hours (Figure 4D). Instead, Ad-MSCs-SF and D-Ad-
MSCs-SF were equally effective and needed 36 hours
to complete the coverage of the scratch area by DFs
(Figure 4E). KCs completed the coverage of the scratch
area in 24 hours and no differences were observed among
the various treatments (Figure 4F).
Ad-MSCs-SF and D-Ad-MSCs-SF secrete angiogenic
molecules in culture medium during endothelial
cells migration
In order to detect the angiogenic molecules released by
Ad-MSCs-SF and D-Ad-MSCs-SF during migration of
HUVECs, CM were collected and analyzed by ELISA. Inparticular, we evaluated the presence of VEGF, FGF2,
TGFβ and EGF, all factors that have been shown to
play an important role in wound angiogenesis [32,33]
(Figure 5). The results were normalized for the growth
factor release by HUVEC co-cultured with untreated SF
patches. In summary, we found a significant increment
of VEGF in Ad-MSCs-SF but not in D-Ad-MSCs-SF
derived-CM (Figure 5A). Although at low concentration,
FGF2 was statistically increased in CM of both Ad-
MSCs-SF and D-Ad-MSCs-SF (Figure 5B) and the con-
centration of TGFβ was almost double in CM derived
from D-Ad-MSCs-SF (Figure 5C). EGF was found in a
very low concentration in CM of both Ad-MSCs-SF and
D-Ad-MSCs-SF (Figure 5D). Additionally, we analyzed
by RT-PCR the gene expression of VEGF, FGF2, TGFβ
and EGF on Ad-MSCs cultured on plastic and on SF
patches to ascertain whether SF patches may alter the
expression of genes involved in the angiogenic stimula-
tion. Compared to Ad-MSCs grown on plastic, Ad-
MSCs-SF showed no significant differences in VEGF,
FGF2 and TGFβ; only EGF expression was significantly
down-modulated (Additional file 6: Figure S6).
Figure 4 Ad-MSCs-SF and D-Ad-MSCs-SF stimulate HUVECs migration by using the scratch test assay. HUVECs, DFs and KCs were cultured
in Ibidi Culture-Insert to confluence. Thereafter, the Ibidi Culture-Insert was removed and cells were co-cultured with control medium or in the
presence of SF, Ad-MSCs-SF or D-Ad-MSCs-SF patches located in transwells (a scheme of the assay is also reported in Additional file 1: Figure S5).
HUVECs (A), DFs (B) and KCs (C) migrated into the inter-space were counted at different intervals of time under microscopy at 20× magnifications
in five random fields. Bars in the figures are the means ± SD of three independent experiments. Each migration test was run in triplicate.
*P <0.05; **P <0.01 versus untreated SF patches. During migration of HUVECs (D), DFs (E) and KCs (F) photographs were taken to establish the
time necessary for the cells to complete the coverage of scratch area. Note that HUVECs stimulated by D-Ad-MSCs-SF patches were the most
efficient in completing the coverage of the scratch area that was completed in 48 hours. In the figure, the dotted white lines indicate the margin
of the scratch. Ad-MSCs-SF, silk fibroin patch cellularized with human adipose-derived mesenchymal stromal cells; D-Ad-MSCs-SF, silk fibroin patch
after human adipose-derived mesenchymal stromal cells removal (decellularization); DFs, dermal fibroblasts; HUVECs, human umbilical vein
endothelial cells; KCs, keratinocytes; SF, silk fibroin.
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microvessels in the aortic ring assay
Since Ad-MSCs-SF and D-Ad-MSCs-SF secrete factors
that stimulate HUVECs migration, we next evaluated
the angiogenic potential of patches using the aortic ring
assay to study the capacity of molecules to affect ex vivo
formation of microvascular structures. To this end,
CM was collected during the co-culture of Ad-MSCs-SF
and D-Ad-MSCs-SF with HUVECs. As shown in
Figure 6, treatment of aorta rings with Ad-MSCs-SF-
and, to a minor extent, with D-Ad-MSCs-SF-derived
CM improved capillary outgrowth. Maximal stimulationof angiogenesis was observed on day 7. At this time of
observation, the number of capillaries in the presence
of Ad-MSCs-SF-derived CM was 45 ± 5; it was 32 ± 8
in D-Ad-MSCs-SF, while in control medium and in
SF-derived CM it was, respectively, 12 ± 6 and 15 ± 4
(Figure 6A). Figure 6B shows photographs of capillary
outgrowth from aortic rings under the different treat-
ment conditions.
Discussion
SF patches are easy to handle, have a great mechanical
strength, support cell adhesion and allow the storage
Figure 5 Ad-MSCs-SF and D-Ad-MSCs-SF release angiogenic factors that stimulate migration of HUVECs. At the end of the HUVECs
scratch test, aliquots of CM were collected. The presence of human VEGF (A), FGF2 (B), TGFβ (C) and EGF (D) were quantified (pg/mL) by ELISA
in accordance with the standard guideline protocol supplied with the kits. The background value (<10%) of each growth factor analyzed and
contained in SCM not cultured with cells was subtracted. The results were normalized for the growth factor release by HUVEC co-cultured with
untreated SF patches. Data are expressed as mean ± SD of the secreted factor. The assay was repeated twice and each sample was run in
triplicate. *P <0.05; **P <0.01 versus HUVECs cultured in the presence of untreated SF patches. Ad-MSCs-SF, silk fibroin patch cellularized with
human adipose-derived mesenchymal stromal cells; CM, conditioned medium; D-Ad-MSCs-SF, silk fibroin patch after human adipose-derived
mesenchymal stromal cells removal (decellularization); EGF, epidermal growth factor; FGF2, fibroblast growth factor 2; HUVECs, human umbilical
vein endothelial cells; SCM, stem cell medium; SF, silk fibroin; TGFβ, transforming growth factor β: VEGF, vascular endothelial growth factor.
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[33-37]. For all these reasons, we have used SF patches
cellularized with Ad-MSCs to test their capacity in im-
proving wound healing in diabetic mice. In addition, we
have examined the effects of D-Ad-MSCs-SF in order to
determine if the presence of living cells at the trans-
plantation site is essential to evoke reparative efficacy
and if D-Ad-MSCs-SF may still retain biological efficacy
in wound repair.
Previous data have shown that MSCs, either applied
alone [32] or associated with SF-chitosan scaffold, dem-
onstrated efficacy in accelerating wound healing in a
murine model of soft tissue injury or in streptozotocin-
induced diabetic rats [29,38]. More recently, O’Brien and
colleagues demonstrated that topical administration of
mesenchymal stem cells seeded in a collagen scaffold
augments wound healing and increases angiogenesis in
the diabetic rabbit ulcer [39].
We, here, significantly expanded these observations
showing for the first time that not only Ad-MSCs-SFpatches accelerate wound repair, but, more importantly,
their decellularized SF counterpart worked as well.
Moreover, different from other studies, we have used the
db/db diabetic mice strain, an experimental animal
model in which wound repair is significantly delayed,
thus mimicking a pathological condition commonly ob-
served in diabetic patients [22,40]. The rationale for
using MSCs combined with SF patches to improve heal-
ing is based on previous experimental evidence showing
that MSCs and SF may work synergistically [41-43].
According to these publications, SF scaffold mimicking a
natural extracellular matrix, favors the adhesion and
proliferation of MSCs and, when applied to a skin
wound, may serve as a delivery substrate for MSCs [29].
On the other hand, the MSCs are considered cells with
an active capacity to release angiogenic and trophic fac-
tors, critical to proper wound regeneration [32,33,44,45]
or are able to differentiate into different cell lineages
[46], including dermal cells [5,29,46]. In this regard, we
clearly demonstrated that decellularized SF patches
Figure 6 Ad-MSCs-SF and D-Ad-MSCs-SF stimulate outgrowth of microvessels in the aorta ring assay. Rat dorsal aorta was excised and
around 1 mm-thick rings were prepared. The rings were placed into 40 uL of collagen solution and incubated at 37°C for 30 minutes to obtain
collagen jellification. At the end of incubation of HUVECs with control medium or SF, Ad-MSCs-SF- and D-Ad-MSCs-SF-derived CM were added. In
A) the quantification of neovessel outgrowth from aortic rings obtained by counting under an inverted microscope at 10× magnifications after
10 days of incubation is reported. Bars are means ± SD of number of neovessel formation. The assay was repeated twice and each sample was
run in triplicate. *P <0.05; **P <0.01 versus rings cultured in the presence of CM derived from HUVECs treated with control SF patches.
Photographs of capillary outgrowth from aorta rings were taken under the different treatment conditions B). Ad-MSCs-SF, silk fibroin patch
cellularized with human adipose-derived mesenchymal stromal cells; CM, conditioned medium; D-Ad-MSCs-SF, silk fibroin patch after human
adipose-derived mesenchymal stromal cells removal (decellularization); HUVEC, human umbilical vein endothelial cells; SF, silk fibroin.
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H2O, that was sufficient to remove all the cells, main-
tained efficacy to accelerate healing. Thus, our data
confirm that MSCs exert their wound healing efficacy
mostly through a paracrine mechanism; therefore, the
presence of live cells on the scaffold may not be needed
[44,45]. Data from Altman et al., suggest a major trans-
differentiation mechanism of human Ad-MSCs seeded
on a SF-chitosan scaffold in enhancing wound repair
[29]. However, they used immunodeficient mice, differ-
ent from our db/db mice model which has an efficient
immune system and, therefore, may rapidly eliminate
the xenogenic human transplanted cells. Here, in the
mice treated with Ad-MSCs-SF, some anti-HuNu posi-
tive cells were found; thus, in mice treated with livecells we cannot completely exclude a mechanism of
transdifferentiation.
In our study, the paracrine mechanism of wound re-
pair was also supported by in vitro experiments. In par-
ticular, by using the scratch test assay, we found that
both Ad-MSCs-SF and D-Ad-MSCs-SF were able to sig-
nificantly stimulate HUVECs and, to a lesser extent, the
DFs, but not KCs migration. Interestingly, the analysis of
CM during HUVECs migration, revealed that VEGF was
highly produced only by Ad-MSCs-SF; in contrast, D-
Ad-MSCs-SF release FGF2 and TFGβ but at very low
levels (respectively, 160 and 540 pg/mL) probably insuf-
ficient per se to stimulate HUVECs migration. Therefore,
while Ad-MSCs-SF may stimulate HUVECs migration
through the release of VEGF, D-Ad-MSCs-SF appear to
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volve the synergic participation of different angiogenic
factors (including perhaps FGF2 and TGFβ).
Concerning the capacity of SF to entrap molecules se-
creted by Ad-MSCs, we observed that D-Ad-MSCs-SF
released FGF2 and TFGβ but not VEGF. Since Ad-
MSCs-SF patches cultured in the absence of HUVECs
did not reduce the expression of VEGF, FGF2 and TGFβ
genes, we conclude that FGF2 and TGFβ may remain
entrapped in the SF fibers while VEGF may not be en-
trapped and even if it remains trapped, it is not released.
It is well known that a SF scaffold can be loaded with
drugs or active growth factors [47,48]; however, whether
SF scaffolds seeded with cells possess differential growth
factors binding properties or a capacity to alter cell-
releasing factors, remains to be further investigated. The
significant down–modulation of Egf gene expression in
Ad-MSCs when seeded on SF patches may suggest that,
at least in vitro, SF may drive Ad-MSCs toward the pro-
duction of growth factors (VEGF, TGFβ and FGF2) that
affect MSCs rather than factors, such as EGF, that affect
mostly neuroectodermal cells, such as KCs [49]. How-
ever, it is not clear if this is also true in vivo. Experi-
ments using only bone marrow MSCs to treat wounds
in diabetic rats showed an increase of the expression of
Egf as well as mesenchymal growth factors [32].
In spite of the ability of SF to bind angiogenic factors
produced by Ad-MSCs in vitro, the RT2 gene profile,
performed in mice treated with cellularized and decellu-
larized SF patches, seems to support our in vitro obser-
vations on angiogenesis. Indeed, albeit the RT2 gene
profile of mice treated with Ad-MSCs-SF demonstrated
a higher involvement of genes that control angiogenesis
than those treated with D-Ad-MSCs-SF, both treatments
seem to enhance the wound healing process through a
mechanism that leads to stimulation of angiogenesis.
Additionally, as the in vivo RT2 gene profile analysis also
revealed that D-Ad-MSCs-SF treated mice may have a
less inflammatory gene expression (in particular Mif and
Il6st were significantly down-modulated), we cannot ex-
clude the possibility that the absence of living xenogenic
cells on the D-Ad-MSCs-SF patches may have less im-
pact in stimulating inflammation, thus favoring skin re-
generation [50].
Conclusions
In conclusion, our results demonstrate that the combin-
ation of Ad-MSCs and SF patches is effective in acceler-
ating wound repair in a model of diabetic mice that
has been shown to have a significantly delayed capacity
of wound healing [22]. More importantly, our study
demonstrates for the first time that an almost equivalent
success in wound repair can be achieved by using decel-
lularized SF patches. Both treatments improve healingthrough a similar mechanism that mainly involves the
release of angiogenic and collagen deposition stimulating
molecules. The removal of the cells from SF patches
may have significant and practical advantages in decreas-
ing the risk of transferring genetically mutated cells and
in reducing the possibility of stimulating the immune
system. Moreover, decellularized patches could be pre-
pared and stored until their use. Further studies will be
performed on SF patches electrospinning with growth
factors released by cell culture. In our opinion, this study
may represent an important step toward the successful
treatment of ulcers in diabetic patients.Additional files
Additional file 1: Figure S1. Phenotypic characterization of Ad-MSCs.
A) Images of cultured human Ad-MSCs at passages three to five were
taken on sub-confluent culture of two different preparations of Ad-MSCs.
Note the typical fibroblastic–like morphology of cells. B) FC analysis of
multiple surface epitopes, showed that Ad-MSCs minimally expressed
(≤2%) hematopoietic cell markers CD14, CD34 and CD45, endothelial
marker CD31 and immunological markers CD19 and HLA-DR. In contrast,
Ad-MSCs highly expressed (≥90%) MSC markers such as CD73, CD90 and
CD105. C) After induction, Ad-MSCs exhibited adipogenic, osteogenic
and chondrogenic potentials which were demonstrated by staining of
lipid droplets, calcium nodules stained and aggrecan deposition with (A),
Oil red-O (B) Alizarin Red and (C ) aggrecan, respectively.
Additional file 2: Figure S2. Ad-MSCs differentiation potential on SF
patches and structural analyses of untreated and decellularized SF
patches. Ad-MSCs seeded on SF patches, under inductive conditions,
differentiated towards adipocytes, osteocytes and chondrocytes as
demonstrated by (A) Oil O Red, (B) Alizarin red stainings and (C) aggrecan
positivity. (D) FTIR-ATR spectra of SF patches. (a) Untreated control sample
(C.I. = 0.69). (b) SF patch sterilized with ethanol 70 vol% and exposed to
UV light for one hour (C.I. = 0.67). (c) Decellularized SF patch stored in
water at 4°C (C.I. = 0.69). (d) Decellularized SF patch stored under dry
conditions at 4°C (C.I. = 0.69). (e) Decellularized SF patch frozen stored in
water at −20°C (C.I. = 0.69). (f) Decellularized SF patch frozen stored under
dry conditions at −20°C (C.I. = 0.69). (A I = amide I; A II = amide II; A III =
amide III). The intrinsic crystalline structure of SF patches was not affected
by any of the treatments carried out on them, from sterilization to
decellularization, freezing and storing under dry or wet conditions
at +4°C or −20°C, as demonstrated by the closely similar profiles and by
the values of crystallinity. (E) DSC thermograms of SF patches. (a) Untreated
control sample (C.I. = 0.69). (b) SF patch sterilized with ethanol 70 vol% and
exposed to UV light for six hours. (c) Decellularized SF patch stored in water
at 4°C. (d) Decellularized SF patch stored under dry conditions at 4°C. (e)
Decellularized SF patch frozen stored in water at −20°C. (f) Decellularized SF
patch frozen stored under dry conditions at −20°C. Sterilization caused a
slight low-temperature broadening of the melting/degradation endotherm,
but the main peak still remained at high temperature (284°C) and the
β-sheet crystalline regions retained their thermal stability, as indicated by
the FTIR results.
Additional file 3: Figure S3. Histological analysis of skin wounds upon
treatment with SF, Ad-MSCs-SF and D-Ad-MSCs-SF patches. On day 14
after treatments, some mice were sacrificed and wounds were
investigated by histology. Control wounds treated with SF patches alone
showed a dermis displaying important hypercellularity, scanty collagen
fiber alignment and continuous epidermis with evident signs of dysplasia
determined by the immature status (A, B). Wounds treated with D-Ad-
MSCs-SF patches showed a more advanced epidermal organization and a
dermis very rich in cells and microvessels (C, D). The wound treated with
Ad-MSCs-SF showed the highest degree of tissue organization (E, F); the
multilayer structure of epidermis was formed, the dermis still showed
hypercellularity with the presence of numerous neoformed small vessels.
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B, D and F are shown, at higher magnifications, the skin of mice treated
with SF, D-Ad-MSCs-SF and Ad-MSCs-SF patches, respectively. In the
figure, wound edges are indicated by arrows; e = epidermis; d = dermis.
Additional file 4: Figure S4. Wound healing process in mouse tissue
by Ad-MSCs-SF and D-Ad-MSCs-SF. In mouse tissues that received SF, Ad-
MSCs-SF and D-Ad-MSCs-SF patches, Col4α1 (A,B,C) and Vegf (D,E,F) were
investigated by immunohistochemistry. Expression of Col4α1was ob-
served in every sample. Basal membrane was continuously and sharply
stained in Ad-MSCs-SF as well as in D-Ad-MSCs-SF demonstrating that
the epidermal-dermal junction had been restored. An average of 10 to
12 spindle shaped Vegf positive cells per field (100× magnification) were
observed in the dermal layer of Ad-MSCs-SF. Conversely, reactive cells in
D-Ad-MSCs-SF treated samples were less numerous (two to four per field,
at 100× magnification) and were characterized by a less intense staining.
A similar number of Vegf positive cells was detected in SF treated
samples. Immunohistochemical staining with anti-HuNu was additionally
performed to demonstrate the ‘fate’ of human transplanted Ad-MSCs in
host tissues. The anti-HuNu antibody reacted with some cells located in
the dermal layer of Ad-MSCs-SF treated skin. An average of three to four
positive cells per field (100× magnification) was detected. Anti-HuNu
reactivity was never observed in D-Ad-MSCs-SF and SF treated skin (G,H,I).
Additional file 5: Figure S5. Scheme of the scratch test assay to
evaluate SF, D-Ad-MSCs-SF and Ad-MSCs-SF activity on cell migration. As
shown in the figure, the scratch assay was set up with an Ibidi Culture-
Insert placed on the bottom of wells in a 24-multiwell plate (A). Human
KCs, DFs and HUVECs seeded into Ibidi Culture-Insert in SCM allow cell
monolayer formation. Thereafter, the Ibidi Culture-Insert was removed
and 0.5 mL of SCM was added. Next, transwells 8-μm Polycarbonate
Membrane Inserts filter were placed on the well and then SF (B), D-Ad-
MSCs-SF (C) and Ad-MSCs-SF (D) were placed into transwells and rapidly
filled with 200 μL of SCM. For HUVECs, transwells were removed after 24
hours or 48 hours and cells were observed under a Zeiss Axiophot-2
microscope. Cells migrated into the inter-space were counted under mi-
croscopy at 20× magnifications in five random fields. Each migration test
was run in triplicate.
Additional file 6: Figure S6. Angiogenic genes expression of Ad-MSCs
seeded on SF patches. RT-PCR was performed to evaluate the gene
expression of VEGF, FGF2, TGFβ and EGF on Ad-MSCs cultured on plastic
and on SF patches. On the ordinate axis is reported the fold of changes
of gene expression of Ad-MSCs on SF patches versus control Ad-MSCs
cultured on plastic. The control of gene expression values was considered
equal to 1. Relative gene expression was calculated by a comparative
method (2-ΔΔCt) using GAPDH as a housekeeping gene. Polymerase chain
reactions were carried out in triplicate. Note that in comparing Ad-MSCs
grown on plastic versus Ad-MSCs-SF, no significant differences in VEGF,
FGF2 and TGFβ were seen; only EGF expression was significantly
down-modulated. *P <0.05 versus SF patches.Abbreviations
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